Latest News
Cancer Doctors Recoil at Experimental Change in Drug Reimbursements
The Associated Press reports that medicare’s proposal for changes to reimbursement processes for chemotherapy and other drugs administered in the office is sparking an uproar across specialist doctors, drugmakers, and some patient advocacy groups, with much of the focus placed on high-cost medications and the ongoing problem of runaway drug costs. Read the AP article posted on www.chicagotribune.com here…
This posting is presented for informational purposes only and does not represent legal or financial guidance. Any opinions or interpretations presented are either those of the original author or, in the case of articles authored by the AMAC Foundation, are the opinions of AMAC Foundation staff, originally trained and accredited by the National Social Security Association (NSSA) and certified via the AMAC Foundation. Any links included in the article are valid on the posted date; socialsecurityreport.org cannot guarantee the duration of the links’ validity. NSSA and the AMAC Foundation and its staff are not affiliated with or endorsed by the Social Security Administration or any other governmental entity. To submit a question, visit our website (https://amacfoundation.org/services/) or email us at ssadvisor@amacfoundation.org. Because we are a non-profit organization, there is no charge for these services.